Thoracic Research and Practice
Case report

Two Cases of Tuberculosis Complicating Treatment With Tumor Necrosis Factor-α Inhibitors

1.

Mersin Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Mersin, Türkiye

2.

Mersin University Scool of Medicine, Physical Treatment and Rehabilitation, Mersin, Turkey

3.

Mersin University Scool of Medicine, Microbiology, Mersin, Turkey

Thorac Res Pract 2008; 9: 133-136
Read: 1536 Downloads: 1204 Published: 18 July 2019

Abstract

TNF-α blocking agents have been increasingly used in the treatment of systemic inflammatory diseases. The main adverse effect of these drugs is susceptibility to infections, mainly reactivation of latent tuberculous infection (LTBI). In this paper we described two cases of TNF-α inhibitor-associated TB. Because LTBI and BCG vaccination are widespread in the Turkish population, a stringent pre-treatment screening protocol for LTBI should be used. In such patients, TB frequently presents as an extrapulmonary or disseminated and life-threatening disease. Physicians should be aware of the risk of the reactivation of TB, despite isoniazid chemoprophylaxis, with unusual clinical manifestations and a paradoxical response. (Tur Toraks Der 2008;9:133-6)

Files
EISSN 2979-9139